Michael Gebel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Gebel has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
Mp Manns
Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology Hannover, Germany
23 shared publicationsK Rifai
Städtisches Klinikum Wolfenbüttel, Department of Gastroenterology, Wolfenbüttel, Germany
19 shared publicationsB Boozari
18 shared publicationsM. P. Manns
14 shared publicationsA Potthoff
Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology Hannover, Germany
13 shared publicationsB. Boozari
11 shared publications
Latest Publications
- 17 May 2018
- Published by Springer Nature in Der Gastroenterologe
- Vol. 13 (4) , 262-263
Ultraschalldiagnostik im Jahr 2018
- 17 May 2018
- Published by Springer Nature in Der Gastroenterologe
- Vol. 13 (4) , 262-263
Ultraschalldiagnostik im Jahr 2018
- 16 May 2018
- Published by Springer Nature in Der Gastroenterologe
- Vol. 13 (4) , 304-310
Sonographie zum Therapiemonitoring beim Morbus Crohn
- 16 May 2018
- Published by Springer Nature in Der Gastroenterologe
- Vol. 13 (4) , 304-310
Sonographie zum Therapiemonitoring beim Morbus Crohn
- 2 March 2017
- Published by Springer Nature
- p. 217-231
Ultrasound in Inflammatory Bowel Disease
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S236
Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S236
Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals
- 9 December 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 54 (12) , 1343-1404
Percutaneous ultrasound-guided cyst sclerotherapy in patients with polycystic liver disease
Background: Polycystic liver disease (PCLD) is a genetic disease causing hepatomegaly and local cystic complications. To date, there is no established medical therapy for PCLD. We present our results of percutaneous minimal-invasive cyst sclerotherapy in patients with PCLD. Patients and methods: 301 pat. with PCLD were followed by our centre between 2001 – 2008 and retrospectively analysed. Mean age was 50 ± 11 years with 19% male. Additional polycystic kidney disease was found in 63% of pat. All pat. received a special questionnaire to report their subjective follow-up. Follow-up was 33 ± 27 months. 31 pat. underwent liver transplantation during this period. A total of 31 pat. died during follow-up, 9 of them with liver-associated cause of death. Cyst sclerotherapy was performed in pat. with a minimum cyst size of 8 – 10 cm or with symptomatic cysts. For sclerotherapy, cyst fluid was aspired with a 20G needle under ultrasound-guidance. Around 10% of the aspired volume was then administered into the cyst in form of 1% ethoxysclerol. In cysts with a diameter of > 15 cm, cyst drainage was performed to empty them first and perform sclerotherapy via drainage thereafter. In infected or sanguinous cysts, they were rinsed with NaCl 0,9% instead of sclerotherapy. Results: A total of 422 cyst therapy sessions of 903 cysts with a mean diameter of 8,1 ± 3,7 cm was performed in 149 pat. (50%). This included 705 sclerotherapies, 33 drainages and 110 cyst rinsing therapies. Indications for cyst therapy were especially symptomatic cysts (67%) and cyst size (48%). The questionnaire of 150 pat. could be analysed, 85 of them underwent cyst therapies leading to a subjective improvement of symptoms in 88% of them. Complications of cyst therapy were noted in 26% of cases, mostly local pain (16%) or inflammatory signs (16%). Bleedings occurred in < 1%. Conclusions: Percutaneous ultrasound-guided cyst sclerotherapy is easy, effective, cheap and with few complications to improve symptoms of patients with PCLD.
- 9 December 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 54 (12) , 1343-1404
Percutaneous ultrasound-guided cyst sclerotherapy in patients with polycystic liver disease
Background: Polycystic liver disease (PCLD) is a genetic disease causing hepatomegaly and local cystic complications. To date, there is no established medical therapy for PCLD. We present our results of percutaneous minimal-invasive cyst sclerotherapy in patients with PCLD. Patients and methods: 301 pat. with PCLD were followed by our centre between 2001 – 2008 and retrospectively analysed. Mean age was 50 ± 11 years with 19% male. Additional polycystic kidney disease was found in 63% of pat. All pat. received a special questionnaire to report their subjective follow-up. Follow-up was 33 ± 27 months. 31 pat. underwent liver transplantation during this period. A total of 31 pat. died during follow-up, 9 of them with liver-associated cause of death. Cyst sclerotherapy was performed in pat. with a minimum cyst size of 8 – 10 cm or with symptomatic cysts. For sclerotherapy, cyst fluid was aspired with a 20G needle under ultrasound-guidance. Around 10% of the aspired volume was then administered into the cyst in form of 1% ethoxysclerol. In cysts with a diameter of > 15 cm, cyst drainage was performed to empty them first and perform sclerotherapy via drainage thereafter. In infected or sanguinous cysts, they were rinsed with NaCl 0,9% instead of sclerotherapy. Results: A total of 422 cyst therapy sessions of 903 cysts with a mean diameter of 8,1 ± 3,7 cm was performed in 149 pat. (50%). This included 705 sclerotherapies, 33 drainages and 110 cyst rinsing therapies. Indications for cyst therapy were especially symptomatic cysts (67%) and cyst size (48%). The questionnaire of 150 pat. could be analysed, 85 of them underwent cyst therapies leading to a subjective improvement of symptoms in 88% of them. Complications of cyst therapy were noted in 26% of cases, mostly local pain (16%) or inflammatory signs (16%). Bleedings occurred in < 1%. Conclusions: Percutaneous ultrasound-guided cyst sclerotherapy is easy, effective, cheap and with few complications to improve symptoms of patients with PCLD.
- 18 August 2016
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 37 (S 01) , SL7_2
Rapid and sustained improvements of liver stiffness values in HCV-infected patients treated with direct-acting antiviral drugs
Background: The use of interferon-free antiviral therapy in patients with chronic HCV infection is associated with high rate of sustained virological response (SVR). The aim of this study was to evaluate changes of liver stiffness (LS) using Acoustic Radiation Force Impulse Imaging (ARFI) elastography and transient elastography (TE) during antiviral treatment and to evaluate its role in relation to SVR. Patients and methods: In total 337 chronic HCV-infected patients (mean age 59 years, 42% females) were included in this prospective single center study. Genotype 1 accounted for 75%, 244 patients (72%) had liver cirrhosis at baseline. Patients received direct-acting antiviral drugs (DAADs). 254 patients (75%) reached follow up 24 (FU24) and were considered for statistical analyses. Duration of treatment varied between 8 and 24 weeks. All patients received LS measurement by ARFI during treatment and at FU24 and FU48. TE was performed at baseline and FU24. Results: SVR was observed in 219/254 patients (86%). Mean ARFI values decreased significantly from baseline to FU48 (p = 0.042), with a gradually decrease from baseline to W4 (p = 0.001), from W4 to W12 (p = 0.004) and from FU24 to FU48 (p = 0.031). Median TE showed an overall decrease from baseline to FU24 (p < 0.001). ARFI values decreased on the LSM scale at W48 from F4 to F3 in 17%, to F2 in 7% and to < F2 26%. Baseline values of ARFI, TE and AST showed higher values in relapsers than in patients with SVR (p < 0.001, p < 0.001, p < 0.029, respectively). In the multivariate analysis, ARFI was the only predictor of liver stiffness regression (p < 0.001). Conclusion: LSM by ARFI and TE decreased in almost all HCV-treated patients during the course of treatment, irrespective of HCV response. Baseline ARFI might be used as predictor of LS regression and HCV response in chronic HCV-infected patients treated with DAADs.
- 18 August 2016
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 37 (S 01) , SL7_2
Rapid and sustained improvements of liver stiffness values in HCV-infected patients treated with direct-acting antiviral drugs
Background: The use of interferon-free antiviral therapy in patients with chronic HCV infection is associated with high rate of sustained virological response (SVR). The aim of this study was to evaluate changes of liver stiffness (LS) using Acoustic Radiation Force Impulse Imaging (ARFI) elastography and transient elastography (TE) during antiviral treatment and to evaluate its role in relation to SVR. Patients and methods: In total 337 chronic HCV-infected patients (mean age 59 years, 42% females) were included in this prospective single center study. Genotype 1 accounted for 75%, 244 patients (72%) had liver cirrhosis at baseline. Patients received direct-acting antiviral drugs (DAADs). 254 patients (75%) reached follow up 24 (FU24) and were considered for statistical analyses. Duration of treatment varied between 8 and 24 weeks. All patients received LS measurement by ARFI during treatment and at FU24 and FU48. TE was performed at baseline and FU24. Results: SVR was observed in 219/254 patients (86%). Mean ARFI values decreased significantly from baseline to FU48 (p = 0.042), with a gradually decrease from baseline to W4 (p = 0.001), from W4 to W12 (p = 0.004) and from FU24 to FU48 (p = 0.031). Median TE showed an overall decrease from baseline to FU24 (p < 0.001). ARFI values decreased on the LSM scale at W48 from F4 to F3 in 17%, to F2 in 7% and to < F2 26%. Baseline values of ARFI, TE and AST showed higher values in relapsers than in patients with SVR (p < 0.001, p < 0.001, p < 0.029, respectively). In the multivariate analysis, ARFI was the only predictor of liver stiffness regression (p < 0.001). Conclusion: LSM by ARFI and TE decreased in almost all HCV-treated patients during the course of treatment, irrespective of HCV response. Baseline ARFI might be used as predictor of LS regression and HCV response in chronic HCV-infected patients treated with DAADs.
- 18 August 2016
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 37 (S 01) , SL11_1
Percutaneous ultrasound-guided cyst sclerotherapy in patients with polycystic liver disease
Purpose: Polycystic liver disease (PCLD) is a genetic disease causing hepatomegaly and local cystic complications. To date, there is no established medical therapy for PCLD. We present our results of percutaneous cyst sclerotherapy in patients with PCLD. Material and methods: 301 pat. with PCLD were followed by our centre between 2001 – 2008 and retrospectively analysed. Mean age was 50 ± 11 years with 19% male. Additional polycystic kidney disease was found in 63%. All pat. received a special questionnaire to report their subjective follow-up. Follow-up was 33 ± 27 months. 31 pat. underwent liver transplantation during this period. A total of 31 pat. died during follow-up. Cyst sclerotherapy was performed in pat. with a minimum cyst size of 8 – 10 cm or with symptomatic cysts. For sclerotherapy, cyst fluid was aspired with a 20G needle under ultrasound-guidance. Around 10% of the aspired volume was then administered into the cyst in form of 1% ethoxysclerol. In cysts with a diameter of > 15 cm, cyst drainage was performed to empty them first and perform sclerotherapy via drainage thereafter. In infected or sanguinous cysts, they were rinsed with NaCl 0.9% instead of sclerotherapy. Results: A total of 422 cyst therapy sessions of 903 cysts with a mean diameter of 8.1 ± 3.7 cm was performed in 149 pat. (50%). This included 705 sclerotherapies, 33 drainages and 110 cyst rinsing therapies. Indications for cyst therapy were especially symptomatic cysts (67%) and cyst size (48%). The questionnaire of 150 pat. could be analysed, 85 of them underwent cyst therapies leading to a subjective improvement of symptoms in 88% of them. Complications of cyst therapy were noted in 26% of cases, mostly local pain (16%) or inflammatory signs (16%). Bleedings occurred in < 1%. Conclusion: Percutaneous ultrasound-guided cyst sclerotherapy is easy, effective, cheap and with few complications to improve symptoms of patients with PCLD.
- 18 August 2016
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 37 (S 01) , SL11_1
Percutaneous ultrasound-guided cyst sclerotherapy in patients with polycystic liver disease
Purpose: Polycystic liver disease (PCLD) is a genetic disease causing hepatomegaly and local cystic complications. To date, there is no established medical therapy for PCLD. We present our results of percutaneous cyst sclerotherapy in patients with PCLD. Material and methods: 301 pat. with PCLD were followed by our centre between 2001 – 2008 and retrospectively analysed. Mean age was 50 ± 11 years with 19% male. Additional polycystic kidney disease was found in 63%. All pat. received a special questionnaire to report their subjective follow-up. Follow-up was 33 ± 27 months. 31 pat. underwent liver transplantation during this period. A total of 31 pat. died during follow-up. Cyst sclerotherapy was performed in pat. with a minimum cyst size of 8 – 10 cm or with symptomatic cysts. For sclerotherapy, cyst fluid was aspired with a 20G needle under ultrasound-guidance. Around 10% of the aspired volume was then administered into the cyst in form of 1% ethoxysclerol. In cysts with a diameter of > 15 cm, cyst drainage was performed to empty them first and perform sclerotherapy via drainage thereafter. In infected or sanguinous cysts, they were rinsed with NaCl 0.9% instead of sclerotherapy. Results: A total of 422 cyst therapy sessions of 903 cysts with a mean diameter of 8.1 ± 3.7 cm was performed in 149 pat. (50%). This included 705 sclerotherapies, 33 drainages and 110 cyst rinsing therapies. Indications for cyst therapy were especially symptomatic cysts (67%) and cyst size (48%). The questionnaire of 150 pat. could be analysed, 85 of them underwent cyst therapies leading to a subjective improvement of symptoms in 88% of them. Complications of cyst therapy were noted in 26% of cases, mostly local pain (16%) or inflammatory signs (16%). Bleedings occurred in < 1%. Conclusion: Percutaneous ultrasound-guided cyst sclerotherapy is easy, effective, cheap and with few complications to improve symptoms of patients with PCLD.
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S720
Rapid and Sustained Improvements of Liver Stiffness Values in HCV-Infected Patients Treated with Direct Antiviral Drugs
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S720
Rapid and Sustained Improvements of Liver Stiffness Values in HCV-Infected Patients Treated with Direct Antiviral Drugs
- Open Access
- 20 May 2015
- Published by Springer Nature in BMC Gastroenterology
- Vol. 15 (1) , 1-7
Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report
Continuous use of anabolic androgenic steroid in high-doses is associated with substantial health risks, including hepatocellular adenoma. Malignant transformation from hepatocellular adenoma to hepatocellular carcinoma after anabolic androgenic steroid abuse has been rarely reported. The morphological distinction of adenoma from well-differentiated hepatocellular carcinoma is challenging and requires elaborated imaging techniques and histology. We report about a 29-year old male professional bodybuilder who presented with mid-epigastric pain at the emergency unit. Ultrasound showed a severe hepatomegaly with multiple lesions. Contrast-enhanced ultrasound revealed a heterogeneous pattern with signs of hepatocellular carcinoma. CT scan of the abdomen confirmed multiple hypervascular lesions and central areas of necrosis without contrast enhancement. Subsequent diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy to establish the diagnosis of a β-catenin and testosterone-receptor positive hepatocellular carcinoma embedded in multiple adenomas. The patient was subsequently treated by liver transplantation and remains tumor-free 27 month after surgery. Hepatocellular carcinoma occurring in association with anabolic androgenic steroid abuse should sensitize physicians and especially professional bodybuilders for the harmful use of high doses of steroids.
- 20 May 2015
- Published by Springer Nature in BMC Gastroenterology
- Vol. 15 (1) , 1-7
Open AccessTestosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report
Continuous use of anabolic androgenic steroid in high-doses is associated with substantial health risks, including hepatocellular adenoma. Malignant transformation from hepatocellular adenoma to hepatocellular carcinoma after anabolic androgenic steroid abuse has been rarely reported. The morphological distinction of adenoma from well-differentiated hepatocellular carcinoma is challenging and requires elaborated imaging techniques and histology. We report about a 29-year old male professional bodybuilder who presented with mid-epigastric pain at the emergency unit. Ultrasound showed a severe hepatomegaly with multiple lesions. Contrast-enhanced ultrasound revealed a heterogeneous pattern with signs of hepatocellular carcinoma. CT scan of the abdomen confirmed multiple hypervascular lesions and central areas of necrosis without contrast enhancement. Subsequent diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy to establish the diagnosis of a β-catenin and testosterone-receptor positive hepatocellular carcinoma embedded in multiple adenomas. The patient was subsequently treated by liver transplantation and remains tumor-free 27 month after surgery. Hepatocellular carcinoma occurring in association with anabolic androgenic steroid abuse should sensitize physicians and especially professional bodybuilders for the harmful use of high doses of steroids.